Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to prospectively evaluate the efficacy and safety of TACE combined with MWA in patients with huge unresectable hepatocellular carcinoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fan Weijun

Criteria

Inclusion Criteria:

1. The performance status of Eastern Cooperative Oncology Group (ECOG) must be 0-1

2. The diagnosis of primary hepatocellular carcinoma must be in line with the American Society for the study of liver diseases (AASLD) diagnostic criteria for hepatocellular carcinoma (HCC)

3. Child-Pugh score A or B;

4. Aged from 18 to 75 years;

5. Subjects voluntarily join the study, and signe informed consent;

6. No anti-tumor therapy was received；

7. Meet the following 4 characteristics: A. primary tumor diameter more than or equal to 10cm; B. no more than 3 HCC foci, and the maximum diameter is less than or equal to 5cm; C. with IIa, I or no portal vein tumor thrombus (Cheng's Classification)；D. the tumor could not be surgically removed

8. No extrahepatic metastases

Exclusion Criteria:

1. Abnormal coagulation function: PLT < 40×109/L, PTA < 40%;

2. Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on;

3. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;

4. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;

5. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;

6. Patients accompanied with other tumors or past medical history of malignancy;

7. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;

8. Allergic to adriamycin chemotherapy drugs，contrast agent and lipiodol;

9. Patients have poor compliance.